2025
Phase II Trial of Reduced‐Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant
Elmariah H, Kim J, Gonzalez R, DiMaggio E, Sansil S, Yoder S, Mishra A, Faramand R, Perez L, Lazaryan A, Mirza A, Khimani F, Liu H, Ochoa‐Bayona J, Nieder M, Perna F, Figura N, Robinson T, Nishihori T, Anasetti C, Pidala J, Bejanyan N. Phase II Trial of Reduced‐Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant. American Journal Of Hematology 2025 PMID: 40492500, DOI: 10.1002/ajh.27738.Peer-Reviewed Original Research
2017
Long‐term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era
Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long‐term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatric Blood & Cancer 2017, 64 PMID: 28646513, DOI: 10.1002/pbc.26696.Peer-Reviewed Original ResearchConceptsGroup D eyesGroup D retinoblastoma eyesD eyesSystemic chemoreductionIntravitreal melphalanSalvage rateRetinoblastoma eyesIntravitreal melphalan injectionRetrospective chart reviewOverall salvage ratePrimary outcome measurementLong-term outcomesExternal beam radiationOcular salvageSalvage therapyVitreous seedsChart reviewGlobe salvageIntravitreal injectionKaplan-MeierTreatment modalitiesTumor recurrenceMelphalan injectionOutcome measurementsMelphalan
2012
Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium
Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. Journal Of NeuroInterventional Surgery 2012, 5: e42. PMID: 23188789, DOI: 10.1136/neurintsurg-2012-010508.rep.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingCerebral AngiographyContrast MediaDrug Delivery SystemsFollow-Up StudiesGadoliniumHumansInfantInjections, Intra-ArterialIntraoperative PeriodMagnetic Resonance AngiographyMaleMelphalanRetinal ArteryRetinal DetachmentRetinal NeoplasmsRetinoblastomaTreatment OutcomeVisual AcuityVerification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium
Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. BMJ Case Reports 2012, 2012: bcr2012010508. PMID: 23162039, PMCID: PMC4545047, DOI: 10.1136/bcr-2012-010508.Peer-Reviewed Original Research
1997
Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 1997, 11: 463-72. PMID: 9509296.Peer-Reviewed Original ResearchConceptsBone marrow CFU-GMMarrow CFU-GMAdministration of decorinParent tumorCFU-GMTumor linesBALB/c miceEffects of secretionsC micePlasma levelsVivo resistanceMonolayer culturesSolid tumorsTherapeutic resistanceTumorsTumor modelDrug resistanceDrug sensitivityDosage rangeThiotepaMelphalanCell linesCisplatinAdministrationAnimals
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvival
1975
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Young R, Chabner B, Hubbard S, Canellos G, DeVita V. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. National Cancer Institute Monograph 1975, 42: 145-8. PMID: 825777.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaOvarian carcinomaHigher overall response rateOral alkylating agentTrials of chemotherapyOverall response ratePAM therapyNational Cancer InstituteIntravenous cyclophosphamideSystemic chemotherapyRemission rateCombination therapyProspective trialsHigh-doseTherapeutic efficacyConventional treatmentResponse rateCancer InstituteChemotherapyAlkylating agentsCarcinomaTherapyTrialsCyclophosphamideMelphalan
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply